Statistik Asas
| CIK | 1593899 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Atea Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan senarai kronologi lengkap bagi Pemfailan SEC, tidak termasuk pemfailan pemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
Calculation of Filing Fee Tables S-8 Atea Pharmaceuticals, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, $0.001 par value per share Other 20,000,000 $ 3.58 $ 71,600,000.00 0.0001531 $ 10,961.96 Tot |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 Atea Pharmaceuticals, Inc. |
|
| August 7, 2025 |
EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update Patient Enrollment Advances in Global Phase 3 Program for Treatment of HCV Four Scientific Posters Presented at EASL, Including Final Results from Phase 2 Study of Bemnifosbuvir/Ruzasvir Regimen Confirming 98% Sustained Virologic Response at 12 Weeks Post-Treatment (SVR12) After Sho |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2025 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiz |
|
| August 7, 2025 |
Power of Attorney (included on signature page) S-8 As filed with the Securities and Exchange Commission on August 7, 2025 Registration No. |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 20, 2025 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiza |
|
| May 12, 2025 |
Exhibit 99.1 Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update Enrollment Ongoing in Phase 3 C-BEYOND Trial for Treatment of HCV Full Phase 2 Results for Regimen of Bemnifosbuvir and Ruzasvir for HCV and Results from Three Additional Phase 1 Studies Supporting Potential Best-in-Class Profile Presented at European Association for the Study of the Liver ( |
|
| May 12, 2025 |
Confidential [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 Atea Pharmaceuticals, Inc. |
|
| May 12, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 12, 2025 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organizat |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule |
|
| April 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 16, 2025 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiz |
|
| April 17, 2025 |
Exhibit 10.1 Execution Version Atea Pharmaceuticals, Inc. 225 Franklin Street, Suite 2100 Boston, Massachusetts 02110 April 16, 2025 Bradley L. Radoff 2727 Kirby Drive Unit 29L Houston, Texas 77098 JEC II Associates, LLC 68 Mazzeo Drive Randolph, Massachusetts 02368 Ladies and Gentlemen: This letter (this “Agreement”) constitutes an agreement by and among (a) Atea Pharmaceuticals, Inc. (the “Compa |
|
| April 17, 2025 |
Exhibit 99.1 Atea Pharmaceuticals Appoints Howard H. Berman to Board of Directors and Announces Share Repurchase Program Enters into Agreement with Bradley L. Radoff and Michael Torok BOSTON – April 17, 2025 – Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea” or “Company”), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for seriou |
|
| April 3, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 1, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2025 (March 31, 2025) Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of |
|
| April 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 1, 2025 (March 31, 2025) Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorpor |
|
| March 26, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| March 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☐ Filed by a Party other than the Registrant ☒ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confide |
|
| March 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2025 (March 21, 2025) Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorpo |
|
| March 24, 2025 |
Exhibit 99.1 Atea Pharmaceuticals Issues Statement Regarding Director Nominations No Shareholder Action is Required at this Time BOSTON, March 21, 2025 (5:54 PM ET) (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today confirm |
|
| March 24, 2025 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 24, 2025 (March 21, 2025) Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of |
|
| March 6, 2025 |
List of Subsidiaries of the Registrant Exhibit 21.1 Legal Name State of Organization Atea Pharmaceuticals Securities Corporation Massachusetts |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39661 ATEA PHARMACEUT |
|
| March 6, 2025 |
EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update Successful End-of-Phase 2 Meeting with FDA and Alignment on Phase 3 Program for Hepatitis C Virus (HCV) Patient Enrollment in Global Phase 3 HCV Program Expected to Start in April 2025 Conference Call at 4:30 pm ET Today BOSTON, Mass., March 6, 2025 – Atea Pharmaceutic |
|
| March 6, 2025 |
Exhibit 10.1(5) atea pharmaceuticals, INC. 2020 INCENTIVE AWARD PLAN Performance-based restricted STOCK Unit Grant Notice Capitalized terms not specifically defined in this Performance-Based Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of Atea Pharmaceuticals, Inc. (the “Company”) |
|
| March 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): March 6, 2025 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiza |
|
| March 6, 2025 |
Insider Trading Compliance Policy Exhibit 19.1 Atea Pharmaceuticals, Inc. Insider Trading Compliance Policy This Insider Trading Compliance Policy (this “Policy”) consists of seven sections: • Section I provides an overview; • Section II sets forth the policies of the Company prohibiting insider trading; • Section III explains insider trading; • Section IV consists of procedures that have been put in place by the Company to preven |
|
| March 6, 2025 |
Exhibit 10.1(6) atea pharmaceuticals, INC. 2020 INCENTIVE AWARD PLAN Performance-based restricted STOCK Unit Grant Notice Capitalized terms not specifically defined in this Performance-Based Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of Atea Pharmaceuticals, Inc. (the “Company”) |
|
| February 24, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 20, 2025 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or orga |
|
| February 14, 2025 |
AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G EXHIBIT 99.1 AGREEMENT REGARDING JOINT FILING OF STATEMENT ON SCHEDULE 13D OR 13G The undersigned agree to file jointly with the Securities and Exchange Commission (the “SEC”) any and all statements on Schedule 13D or Schedule 13G or Forms 3, 4 or 5(and any amendments or supplements thereto) required under section 13(d) and 16(a) of the Securities Exchange Act of 1934, as amended, in connection wi |
|
| January 14, 2025 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 13, 2025 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organ |
|
| January 14, 2025 |
Exhibit 99.1 Atea Pharmaceuticals to Highlight 2025 Strategic Priorities at the 43rd Annual J.P. Morgan Healthcare Conference Global Phase 3 HCV Program Expected to Initiate in 1Q 2025 Potential Best-in-Class Profile of Bemnifosbuvir + Ruzasvir Regimen Supports Opportunity to Disrupt and Expand Global HCV Market of Approximately $3 Billion in Annual Net Sales The Regimen, if Approved, Should Play |
|
| December 16, 2024 |
BML Capital Management, LLC 65 E Cedar, Suite 2, Zionsville, IN 46077 BML Capital Management, LLC 65 E Cedar, Suite 2, Zionsville, IN 46077 December 13, 2024 Board of Directors Atea Pharmaceuticals, Inc. |
|
| November 15, 2024 |
Atea Pharmaceuticals, Inc. 225 Franklin Street, Suite 2100 Boston, MA 02110 Atea Pharmaceuticals, Inc. 225 Franklin Street, Suite 2100 Boston, MA 02110 November 15, 2024 Via EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Re: Atea Pharmaceuticals, Inc. Registration Statement on Form S-3 Filed November 7, 2024 File No. 333-283073 To whom it may concern: Pursuant to Rule 461(a) under |
|
| November 14, 2024 |
AVIR / Atea Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 avir13ga3.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 3) Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04683R106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appr |
|
| November 7, 2024 |
EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update Topline SVR12 Results from Global Phase 2 Hepatitis C Virus (HCV) Study (N=275) Expected Q4’24 New Data Supportive of HCV Combination to be Presented at the American Association for the Study of Liver Diseases’ (AASLD’s) The Liver Meeting 2024 Pharmacokinetic Data for Bemnifosbuvir t |
|
| November 7, 2024 |
Exhibit 1.2 AMENDED AND RESTATED OPEN MARKET SALE AGREEMENTSM November 7, 2024 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and Jefferies LLC, as sales agent and/or principal (the “Agent”) are parties to that certain Open Market Sale AgreementSM dated November 24, 2021 (the “Original Agreement”) |
|
| November 7, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Atea Pharmaceuticals, Inc. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 Atea Pharmaceuticals, Inc. |
|
| November 7, 2024 |
As filed with the Securities and Exchange Commission on November 7, 2024 Form S-3 Table of Contents As filed with the Securities and Exchange Commission on November 7, 2024 Registration No. |
|
| November 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2024 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organ |
|
| August 7, 2024 |
Non-Employee Director Compensation Program Exhibit 10.1 Atea Pharmaceuticals, Inc. Non-Employee Director Compensation Program (Effective June 20, 2024) Non-employee members of the board of directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program |
|
| August 7, 2024 |
Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 2 Hepatitis C Virus (HCV) Study; Complete SVR12 Results Expected 4Q’24 Bemnifosbuvir and Ruzasvir HCV Data Presented at EASL: Support Best-in-Class Potential with High Antiviral Potency, Low Risk of Drug Interaction, Short Treatment Duration and High |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 Atea Pharmaceuticals, Inc. |
|
| August 7, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 7, 2024 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiz |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 21, 2024 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiza |
|
| June 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 14, 2024 |
Exhibit 99.1 Atea Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Business Update Full Enrollment Achieved in Global Phase 3 SUNRISE-3 Trial for Treatment of COVID-19 with Results Expected 2H’24 Global Phase 2 HCV Study On Track to Report Complete SVR12 Results 2H’24 Multiple Presentations Showcasing Preclinical and New Phase 2 Efficacy Data to be Presented at European As |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 Atea Pharmaceuticals, Inc. |
|
| May 14, 2024 |
Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 14, 2024 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organizat |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| February 28, 2024 |
Exhibit 10.1(4) atea pharmaceuticals, INC. 2020 INCENTIVE AWARD PLAN Performance-based restricted STOCK Unit Grant Notice Capitalized terms not specifically defined in this Performance-Based Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of Atea Pharmaceuticals, Inc. (the “Company”) |
|
| February 28, 2024 |
EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update Final Results Confirm 98% Sustained Virologic Response Rate at Week 4 Post-Treatment (SVR4) from Lead-in Cohort in Phase 2 HCV Study Enrollment in Phase 3 SUNRISE-3 Study Has Surpassed 1,400 COVID-19 Patients in Monotherapy Population; Two Interim Analyses by Independe |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2024 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or orga |
|
| February 28, 2024 |
Policy for Recovery of Erroneously Awarded Compensation Exhibit 97.1 ATEA PHARMACEUTICALS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Atea Pharmaceuticals, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of October 2, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subject |
|
| February 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39661 ATEA PHARMACEUT |
|
| February 28, 2024 |
Exhibit 10.1(3) atea pharmaceuticals, INC. 2020 INCENTIVE AWARD PLAN Performance-based restricted STOCK Unit Grant Notice Capitalized terms not specifically defined in this Performance-Based Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of Atea Pharmaceuticals, Inc. (the “Company”) |
|
| February 28, 2024 |
List of Subsidiaries of the Registrant Exhibit 21.1 Legal Name State of Organization Atea Pharmaceuticals Securities Corporation Massachusetts |
|
| February 14, 2024 |
AVIR / Atea Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 14, 2024 |
AVIR / Atea Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 avir13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 14, 2024 |
AVIR / Atea Pharmaceuticals, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 13, 2024 |
AVIR / Atea Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SC 13G/A 1 tv0355-ateapharmaceuticalsin.htm SCHEDULE 13G/A SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Atea Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 04683R106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box t |
|
| February 13, 2024 |
AVIR / Atea Pharmaceuticals, Inc. / Sommadossi Jean-Pierre - SC 13G/A Passive Investment SC 13G/A 1 d778503dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 3)* Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, pa |
|
| February 7, 2024 |
AVIR / Atea Pharmaceuticals, Inc. / BML Investment Partners, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* (Name of Issuer) Atea Pharmaceuticals, Inc. (Title of Class of Securities) Common Stock, par value $0.001 (CUSIP Number) 04683R106 December 31, 2023 (D |
|
| February 7, 2024 |
AVIR / Atea Pharmaceuticals, Inc. / BML Investment Partners, L.P. Passive Investment SC 13G/A 1 avir13g.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. 1 )* (Name of Issuer) Atea Pharmaceuticals, Inc. (Title of Class of Securities) Common Stock, par value $0.001 (CUSIP Number) 04683R1 |
|
| November 28, 2023 |
AVIR / Atea Pharmaceuticals Inc / TANG CAPITAL PARTNERS LP - AMENDMENT NO. 1 Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the securities exchange act of 1934 (amendment no. |
|
| November 8, 2023 |
Exhibit 99.1 Atea Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update Patient enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19; first interim analysis expected 1Q24 Phase 2 bemnifosbuvir and ruzasvir combination trial for hepatitis C (HCV) advances, initial results from 60-patient lead-in cohort expected 1Q24 Confere |
|
| November 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| November 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 8, 2023 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organ |
|
| October 2, 2023 |
AVIR / Atea Pharmaceuticals Inc / BML Investment Partners, L.P. Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2 (AMENDMENT NO. )* (Name of Issuer) Atea Pharmaceuticals, Inc. (Title of Class of Securities) Common Stock, par value $0.001 (CUSIP Number) 04683R106 September 25, 2023 (Date |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| August 8, 2023 |
Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2023 Financial Results and Provides Business Update • Enrollment continues in global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 • Phase 3 SUNRISE-3 trial protocol amended to broaden eligibility criteria for high-risk patients and adapt to current COVID-19 environment • Enrollment continues in Phase 2 t |
|
| August 8, 2023 |
Non-Employee Director Compensation Program Exhibit 10.1 ATEA PHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (Effective June 15, 2023) Non-employee members of the board of directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non- Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program |
|
| August 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2023 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiz |
|
| August 8, 2023 |
Form of Non-Employee Director Stock Option Award Agreement Exhibit 10.2 ATEA PHARMACEUTICALS, INC. 2020 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Capitalized terms not specifically defined in this Stock Option Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of Atea Pharmaceuticals, Inc. (the “Company”). The Company has granted to the participant listed below |
|
| August 8, 2023 |
Form of Non-Employee Director Restricted Stock Unit Award Agreement Exhibit 10.3 ATEA PHARMACEUTICALS, INC. 2020 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT GRANT NOTICE Capitalized terms not specifically defined in this Restricted Stock Unit Grant Notice (the “Grant Notice”) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the “Plan”) of Atea Pharmaceuticals, Inc. (the “Company”). The Company has granted to the partic |
|
| June 21, 2023 |
Amended and Restated Bylaws of Atea Pharmaceuticals, Inc., marked to show changes Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ATEA PHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PROCEDURES |
|
| June 21, 2023 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF ATEA PHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PRO |
|
| June 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 16, 2023 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiza |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin |
|
| May 22, 2023 |
AVIR / Atea Pharmaceuticals Inc / TANG CAPITAL PARTNERS LP Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the securities exchange act of 1934 (amendment no. |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 8, 2023 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organizati |
|
| May 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| May 8, 2023 |
EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update Global Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; execution of global geographic footprint Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV on track for first patient do |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a‑6(e)(2)) ☐ Defin |
|
| February 28, 2023 |
EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for treatment of COVID-19 in high-risk patients continues enrollment; interim analysis expected in 2H23 Phase 2 trial evaluating combination of bemnifosbuvir and ruzasvir for treatment of HCV to start enrollment in 2Q23; |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39661 ATEA PHARMACEUT |
|
| February 28, 2023 |
Non-Employee Director Compensation Program Exhibit 10.3 Atea Pharmaceuticals, Inc. Non-Employee Director Compensation Program (Effective June 17, 2022) Non-employee members of the board of directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program |
|
| February 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2023 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or orga |
|
| February 28, 2023 |
List of Subsidiaries of the Registrant Exhibit 21.1 Legal Name State of Organization Atea Pharmaceuticals Securities Corporation Massachusetts |
|
| February 10, 2023 |
AVIR / Atea Pharmaceuticals Inc / Sommadossi Jean-Pierre - SC 13G/A Passive Investment SC 13G/A 1 d420198dsc13ga.htm SC 13G/A United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 2)* Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, pa |
|
| February 10, 2023 |
AVIR / Atea Pharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 avia13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| February 9, 2023 |
AVIR / Atea Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Atea Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 04683R106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is fi |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| November 7, 2022 |
EX-99.1 Exhibit 99.1 Atea Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Business Update Enrollment of SUNRISE-3 Global Phase 3 Registrational Trial of Bemnifosbuvir in High-Risk Non-Hospitalized Patients with COVID-19 Expected Before Year-End 2022 Completion of Patient Enrollment Expected Around Year-End 2022 for AT-752 U.S. Human Challenge Study and for First Cohort of |
|
| November 7, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 7, 2022 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organ |
|
| August 8, 2022 |
Exhibit 99.1 Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update Advancing Bemnifosbuvir to Late-Stage Development for COVID-19 Following Meetings with U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) Emergency Task Force New Data Demonstrate Bemnifosbuvir Retained Antiviral Activity Against Omicron Subvariant In Vitro Progress |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 8, 2022 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiz |
|
| August 8, 2022 |
Consulting Agreement dated June 10, 2022, by and between the Company and Bruce Polsky, M.D. Exhibit 10.2 CONSULTING AGREEMENT This CONSULTING AGREEMENT (this ?Agreement?), is made this 10th day of June, 2022 by Atea Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Bruce Polsky, M.D. (the ?Consultant?). INTRODUCTION The Company and the Consultant desire to establish the terms and conditions under which the Consultant will provide services to the Company. In consideration |
|
| August 8, 2022 |
Amendment to Sublease Agreement dated April 11, 2022 between the Company and DataRobot, Inc. 1 Exhibit 10.1 AMENDMENT OF SUBLEASE THIS AMENDMENT OF SUBLEASE (?Amendment?) is made as of this day of April, 2022 by and between DataRobot, Inc., a Delaware corporation, having an office at 225 Franklin Street, Boston, MA 02110 (?Sublandlord?), and Atea Pharmaceuticals, Inc., a Delaware corporation having an office at 125 Summer Street, Boston, MA 02110 (?Subtenant?). R E C I T A L S: A. Pursuan |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| June 21, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 17, 2022 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiza |
|
| May 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| May 10, 2022 |
As filed with the Securities and Exchange Commission on May 10, 2022 As filed with the Securities and Exchange Commission on May 10, 2022 Registration No. |
|
| May 10, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 10, 2022 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organizat |
|
| May 10, 2022 |
Exhibit 99.1 Atea Pharmaceuticals Reports First Quarter 2022 Financial Results and Provides Business Update New clinical results from MORNINGSKY trial shows 71% reduction in hospitalization (secondary endpoint) in broad patient population with COVID-19 treated with bemnifosbuvir (AT-527) versus placebo (p=0.047, unadjusted, exploratory) New clinical results from final analysis of Phase 2 hospitali |
|
| April 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Defin |
|
| April 29, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14 |
|
| March 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Atea Pharmaceuticals, Inc. |
|
| March 1, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
Exhibit 99.1 Atea Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update Developing bemnifosbuvir (AT-527), a nucleotide analog, as preferred backbone of combination therapy for COVID-19, progressing to Phase 2 combination clinical trial in 2H 2022 Initiating Phase 2 combination clinical trial of bemnifosbuvir and ruzasvir (RZR) as potential best-i |
|
| February 28, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Atea Pharmaceuticals, Inc. |
|
| February 28, 2022 |
As filed with the Securities and Exchange Commission on February 28, 2022 Table of Contents As filed with the Securities and Exchange Commission on February 28, 2022 Registration No. |
|
| February 28, 2022 |
Exhibit 10.1.2 atea pharmaceuticals, INC. 2020 INCENTIVE AWARD PLAN Performance-based restricted STOCK Unit Grant Notice Capitalized terms not specifically defined in this Performance-Based Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the ?Plan?) of Atea Pharmaceuticals, Inc. (the ?Company?). |
|
| February 28, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39661 ATEA PHARMACEUT |
|
| February 28, 2022 |
Exhibit 10.1.1 atea pharmaceuticals, INC. 2020 INCENTIVE AWARD PLAN Performance-based restricted STOCK Unit Grant Notice Capitalized terms not specifically defined in this Performance-Based Restricted Stock Unit Grant Notice (the ?Grant Notice?) have the meanings given to them in the 2020 Incentive Award Plan (as amended from time to time, the ?Plan?) of Atea Pharmaceuticals, Inc. (the ?Company?). |
|
| February 28, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): February 28, 2022 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or orga |
|
| February 28, 2022 |
Exhibit 10.5 Confidential [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. EXECUTION VERSION LICENSE AGREEMENT by and between MSD INTERNATIONAL GMBH and ATEA PHARMACEUTICALS, INC. Confidential Confidential LICENSE AGREEMENT THIS LICENSE AGR |
|
| February 28, 2022 |
Non-Employee Director Compensation Program Exhibit 10.3 Atea Pharmaceuticals, Inc. Non-Employee Director Compensation Program (Effective June 18, 2021) Non-employee members of the board of directors (the ?Board?) of Atea Pharmaceuticals, Inc. (the ?Company?) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this ?Program?). The cash and equity compensation described in this Program |
|
| February 28, 2022 |
List of Subsidiaries of the Registrant Exhibit 21.1 Legal Name State of Organization Atea Pharmaceuticals Securities Corporation Massachusetts |
|
| February 16, 2022 |
AVIR / Atea Pharmaceuticals Inc / Morningside Venture Investments Ltd - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ATEA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ATEA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| February 14, 2022 |
AVIR / Atea Pharmaceuticals Inc / Cormorant Asset Management, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 10, 2022 |
AVIR / Atea Pharmaceuticals Inc / Sommadossi Jean-Pierre - SC 13G/A Passive Investment United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to ? 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to ? 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)* Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of Secur |
|
| February 9, 2022 |
AVIR / Atea Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Atea Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 04683R106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): January 10, 2022 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organ |
|
| January 10, 2022 |
June 2020 JP Morgan Healthcare Conference January 10, 2022 Exhibit 99.1 Forward-Looking Statements This presentation contains ?forward-looking statements? within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based on our current beliefs, expectations and assumption |
|
| December 10, 2021 |
AVIR / Atea Pharmaceuticals Inc / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04683R106 (CUSIP Number) December 1, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the |
|
| November 26, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 26, 2021 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or orga |
|
| November 24, 2021 |
Exhibit 1.2 Execution Version OPEN MARKET SALE AGREEMENTSM November 24, 2021 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Atea Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the ?Agent?), shares o |
|
| November 24, 2021 |
Exhibit 4.3 ATEA PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 5 Section 2.1. Issuable in Series 5 Section 2.2. Establ |
|
| November 24, 2021 |
As filed with the Securities and Exchange Commission on November 24, 2021 Table of Contents As filed with the Securities and Exchange Commission on November 24, 2021 Registration No. |
|
| November 16, 2021 |
Termination of a Material Definitive Agreement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 12, 2021 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or orga |
|
| November 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| November 12, 2021 |
Exhibit 99.1 Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Third Quarter 2021 Financial Results Phase 3 MORNINGSKY Protocol Amendment to Include New Primary Endpoint, Refined Patient Population and Increased Dose, with Plan to Accelerate Completion of Enrollment Infectious Virus Data Demonstrate AT-527?s Rapid and Potent Antiviral Activity Against COVID-19 in Phase 2 MOON |
|
| November 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 11, 2021 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or orga |
|
| September 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| September 3, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| August 12, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 12, 2021 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organi |
|
| August 12, 2021 |
EXHIBIT 10.3 CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED WITH [***], HAS BEEN EXCLUDED PURSUANT TO REGULATION S-K, ITEM 601(B)(10). SUCH EXCLUDED INFORMATION IS NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. Execution Version Confidential License Agreement This Agreement is entered into with effect as of the Effective Date (as |
|
| August 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| August 12, 2021 |
Exhibit 99.1 Atea Pharmaceuticals Provides Clinical and Corporate Update and Reports Second Quarter 2021 Financial Results ? New Data in Healthy Volunteers Confirmed that AT-527?s Active Metabolite Achieved Target Antiviral Levels in Lungs, Key Site of COVID-19 Infection ? AT-527 Phase 2 Study Interim Results Showed Potent and Rapid Antiviral Activity in Hospitalized Patients; Study to Advance wit |
|
| July 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 19, 2021 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiza |
|
| July 23, 2021 |
Sublease Agreement, dated as of July 19, 2021, by and between the Company and DataRobot, Inc. Exhibit 10.1 SUBLEASE THIS AGREEMENT OF SUBLEASE (?Sublease?) made as of July 19, 2021, by and between DataRobot, Inc., a Delaware corporation, having an office at 225 Franklin Street, Boston, MA 02110 (?Sublandlord?), and Atea Pharmaceuticals, Inc., a Delaware corporation, having an office at 125 Summer Street, Boston, MA 02110 (?Subtenant?). W I T N E S S E T H: A. Pursuant to an Office Lease Ag |
|
| June 21, 2021 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): June 18, 2021 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiza |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 18, 2021 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organizat |
|
| May 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| May 20, 2021 |
Exhibit 10.1 CONSULTING AGREEMENT This CONSULTING AGREEMENT (this ?Agreement?), is made this 18th day of May, 2021 by Atea Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), and Upstream Wellness and Health LLC, an Indiana limited liability company (the ?Consultant?). INTRODUCTION The Company and the Consultant desire to establish the terms and conditions under which the Consultant wil |
|
| May 13, 2021 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): May 13, 2021 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organ |
|
| May 13, 2021 |
Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update Exhibit 99.1 Atea Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update ? Global Phase 3 MORNINGSKY trial of AT-527 in the outpatient setting recently initiated for the treatment of COVID-19 ? Enrollment advancing in Phase 1a trial of AT-752; drug candidate being developed for the treatment of dengue fever BOSTON, Mass., May 13, 2021 ? Atea Pharmaceuticals, Inc |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| April 29, 2021 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 29, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. |
|
| April 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): April 15, 2021 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or organiz |
|
| April 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1 )* ATEA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04683R106 (CUSIP Number) April 1, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| April 7, 2021 |
EXHIBIT 1 AGREEMENT This Joint Filing Agreement, dated as of April 07, 2021, is by and among RA Capital Management, L. |
|
| March 30, 2021 |
Employment Agreement between the Company and Arantxa Horga, MD, dated November 3, 2020 EX-10.9 4 avir-ex109177.htm EX-10.9 Exhibit 10.9 Employment Agreement This Employment Agreement (this “Agreement”), dated as of November 3, 2020 (the “Effective Date”), is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Maria Arantxa Horga, M.D. (“Executive”) (collectively referred to herein as the “Parties” or indivi |
|
| March 30, 2021 |
Employment Agreement between the Company and Janet Hammond, MD, PhD, dated November 3, 2020 Exhibit 10.8 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of November 3, 2020 (the ?Effective Date?), is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Janet Hammond, M.D., Ph.D. (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?). R |
|
| March 30, 2021 |
List of Subsidiaries of the Registrant Exhibit 21.1 Legal Name State of Organization Atea Pharmaceuticals Securities Corporation Massachusetts |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-39661 ATEA PHARMACEUT |
|
| March 30, 2021 |
Employment Agreement between the Company and Wayne Foster, dated November 3, 2020 Exhibit 10.11 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of November 3, 2020, is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and Wayne Foster (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?), and will become effective, if at all, |
|
| March 30, 2021 |
Employment Agreement between the Company and John Vavricka, dated November 3, 2020 Exhibit 10.10 Employment Agreement This Employment Agreement (this ?Agreement?), dated as of November 3, 2020 (the ?Effective Date?), is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the ?Company?), and John Vavricka (?Executive?) (collectively referred to herein as the ?Parties? or individually referred to as a ?Party?). RECITALS A. I |
|
| March 30, 2021 |
Exhibit 4.2 DESCRIPTION OF THE REGISTRANT?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED As of December 31, 2020, Atea Pharmaceuticals, Inc. had one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the ?Exchange Act?). References herein to ?we,? ?us,? ?our? and the ?Company? refer to Atea Pharmace |
|
| February 16, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned, being duly authorized thereunder, hereby execute this agreement as an exhibit to this Schedule 13G to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, to file this Schedule 13G (including amendments thereto) jointly on behalf of each such party. MORNINGSI |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ATEA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2020 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which t |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ATEA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 04683R106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate t |
|
| February 10, 2021 |
SC 13G United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.001 (Title of Class of |
|
| December 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39661 ATEA PHARMACEUTICALS, INC. |
|
| November 13, 2020 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of November 13, 2020, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund I, LP, Cormorant Private Healthcare GP, LLC, Cormorant Private Healthcare Fund II, LP, Cormorant Private Healthcare GP II, LLC, Cormorant Asset Management, LP and Bihua Che |
|
| November 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Atea Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 04683R106 (CUSIP Number) November 3, 2020? (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| November 12, 2020 |
Form of Lock-up Agreement LOCK-UP AGREEMENT Exhibit C Form of Lock-up Agreement LOCK-UP AGREEMENT October 9, 2020 J.P. MORGAN SECURITIES LLC MORGAN STANLEY & CO. LLC EVERCORE GROUP L.L.C. WILLIAM BLAIR & COMPANY, L.L.C. As Representatives of the several Underwriters listed in Schedule 1 to the Underwriting Agreement referred to below c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Morgan Stanley & Co. LLC 1585 Broad |
|
| November 12, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D (Rule 13d-101) Information to be Included in Statements Filed Pursuant to ? 240. |
|
| November 12, 2020 |
AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D Exhibit A AGREEMENT REGARDING THE JOINT FILING OF SCHEDULE 13D The undersigned being duly authorized thereunto, hereby execute this agreement as an exhibit to this Schedule 13D to evidence the agreement of the below-named parties, in accordance with the rules promulgated pursuant to the Securities Exchange Act of 1934, as amended, to file this Schedule 13D (including amendments thereto) jointly on behalf of each such party. |
|
| November 5, 2020 |
Restated Certificate of Incorporation. EX-3.1 Exhibit 3.1 RESTATED CERTIFICATE OF INCORPORATION OF ATEA PHARMACEUTICALS, INC. The name of the corporation is Atea Pharmaceuticals, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on July 12, 2012. This Restated Certificate of Incorporation of the corporation, which restates and |
|
| November 5, 2020 |
8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): November 3, 2020 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 001-39661 46-0574869 (State or other jurisdiction of incorporation or o |
|
| November 5, 2020 |
EX-3.2 Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ATEA PHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PRO |
|
| October 30, 2020 |
SARS-CoV-2 replication process 424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration No. 333-249404 PROSPECTUS 12,500,000 Shares Common Stock This is Atea Pharmaceuticals, Inc.’s initial public offering. We are offering 12,500,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. The initial public offering price of our common stock is $24.00 per share. The |
|
| October 30, 2020 |
Certificate of Amendment to Certificate of Incorporation of the Registrant (currently in effect). EX-4.1.1 Exhibit 4.1.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATEA PHARMACEUTICALS, INC. Atea Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: That the Board of Directors of the Corporation duly adopted resolutions recomme |
|
| October 30, 2020 |
EX-4.3 Exhibit 4.3 RESTATED CERTIFICATE OF INCORPORATION OF ATEA PHARMACEUTICALS, INC. The name of the corporation is Atea Pharmaceuticals, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on July 12, 2012. This Restated Certificate of Incorporation of the corporation, which restates and |
|
| October 30, 2020 |
S-8 As filed with the Securities and Exchange Commission on October 30, 2020 Registration No. |
|
| October 29, 2020 |
CORRESP October 29, 2020 VIA EDGAR Division of Corporation Finance Office of Life Sciences United States Securities and Exchange Commission 100 F Street, N. |
|
| October 29, 2020 |
S-1MEF As filed with the Securities and Exchange Commission on October 29, 2020 Registration No. |
|
| October 27, 2020 |
Underwriter Acceleration Request October 27, 2020 Division of Corporation Finance Securities and Exchange Commission 100 F Street, N. |
|
| October 27, 2020 |
Company Acceleration Request October 27, 2020 Via EDGAR Transmission United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 26, 2020 |
2020 Incentive Award Plan and form of agreements thereunder EX-10.2 Exhibit 10.2 ATEA PHARMACEUTICALS, INC. 2020 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. Capitalized terms used in the Plan are defined in Article XI. ARTICLE |
|
| October 26, 2020 |
EX-3.3 Exhibit 3.3 RESTATED CERTIFICATE OF INCORPORATION OF ATEA PHARMACEUTICALS, INC. The name of the corporation is Atea Pharmaceuticals, Inc. The corporation was originally incorporated by the filing of its original Certificate of Incorporation with the Secretary of State of the State of Delaware on July 12, 2012. This Restated Certificate of Incorporation of the corporation, which restates and |
|
| October 26, 2020 |
Form of Certificate of Amendment to Certificate of Incorporation of Registrant Exhibit 3.1.1 CERTIFICATE OF AMENDMENT TO AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATEA PHARMACEUTICALS, INC. Atea Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: FIRST: That the Board of Directors of the Corporation duly adopted resolutions recommending and |
|
| October 26, 2020 |
EX-3.4 Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ATEA PHARMACEUTICALS, INC. (a Delaware corporation) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 SPECIAL MEETING 1 2.4 ADVANCE NOTICE PROCEDURES FOR BUSINESS BROUGHT BEFORE A MEETING 2 2.5 ADVANCE NOTICE PRO |
|
| October 26, 2020 |
Non-Employee Director Compensation Program EX-10.4 Exhibit 10.4 ATEA APHARMACEUTICALS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM Non-employee members of the board of directors (the “Board”) of Atea Pharmaceuticals, Inc. (the “Company”) shall receive cash and equity compensation as set forth in this Non-Employee Director Compensation Program (this “Program”). The cash and equity compensation described in this Program shall be paid or |
|
| October 26, 2020 |
2020 Employee Stock Purchase Plan EX-10.3 Exhibit 10.3 ATEA PHARMACEUTICALS, INC. 2020 EMPLOYEE STOCK PURCHASE PLAN ARTICLE I. PURPOSE The purposes of this Atea Pharmaceuticals, Inc. 2020 Employee Stock Purchase Plan (as it may be amended or restated from time to time, the “Plan”) are to assist Eligible Employees of Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and its Designated Subsidiaries in acquiring a s |
|
| October 26, 2020 |
Amendment 2 to Form S-1 Table of Contents As filed with the Securities and Exchange Commission on October 26, 2020 Registration No. |
|
| October 26, 2020 |
8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Atea Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 46-0574869 (State of incorporation or organization) (I.R.S. Employer Identification No.) 125 Summer |
|
| October 26, 2020 |
Form of Indemnification Agreement for Directors and Officers EX-10.5 Exhibit 10.5 ATEA PHARMACEUTICALS, INC. INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of , 20[20] between Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and [Name] (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors, officers or in other |
|
| October 26, 2020 |
Employment Agreement between the Company and Andrea Corcoran, dated October 25, 2020 EX-10.10 Exhibit 10.10 Employment Agreement This Employment Agreement (this “Agreement”), dated as of October 25, 2020, is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Andrea Corcoran (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will become effective |
|
| October 26, 2020 |
Employment Agreement between the Company and Jean-Pierre Sommadossi, Ph.D., dated October 25, 2020 EX-10.9 Exhibit 10.9 Employment Agreement This Employment Agreement (this “Agreement”), dated as of October 25, 2020, is made by and between Atea Pharmaceuticals, Inc., a Delaware corporation (together with any successor thereto, the “Company”), and Jean-Pierre Sommadossi, Ph.D. (“Executive”) (collectively referred to herein as the “Parties” or individually referred to as a “Party”), and will beco |
|
| October 26, 2020 |
Form of Underwriting Agreement EX-1.1 Exhibit 1.1 Atea Pharmaceuticals, Inc. [●] Shares of Common Stock Underwriting Agreement [●], 2020 J.P. Morgan Securities LLC Morgan Stanley & Co. LLC Evercore Group L.L.C. William Blair & Company, L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Morgan Stanley & Co. LLC 1585 Broa |
|
| October 23, 2020 |
EX-10.8 3 d913778dex108.htm EX-10.8 Exhibit 10.8 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. Execution Version Confidential License Agreement This Agreement is entered into with effect as of the Effective Date (as d |
|
| October 23, 2020 |
Amendment 1 to form S-1 Table of Contents As filed with the Securities and Exchange Commission on October 22, 2020 Registration No. |
|
| October 23, 2020 |
Fourth Amended and Restated Stockholders Agreement, as amended EX-4.1 Exhibit 4.1 ATEA PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT THIS FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of May 19, 2020, by and among Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Founder (as defined below), each of the investors listed on Schedule A hereto (together with any subsequent invest |
|
| October 9, 2020 |
2013 Stock Incentive Plan, as amended, and form of agreements thereunder EX-10.1 Exhibit 10.1 ATEA PHARMACEUTICALS, INC. 2013 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better a |
|
| October 9, 2020 |
Bylaws of the Registrant, as amended (currently in effect) EX-3.2 Exhibit 3.2 AMENDMENT NO. 1 TO BYLAWS OF ATEA PHARMACEUTICALS, INC. (a Delaware corporation) Adopted as of June 29, 2018 This Amendment No. 1 (this “Amendment”) to the Bylaws of Atea Pharmaceuticals, Inc. (the “Corporation”) is made as of June 29, 2018 and adopted by the stockholders of the Corporation. Any term used herein that is not otherwise defined shall have the meaning ascribed to su |
|
| October 9, 2020 |
Fourth Amended and Restated Stockholders Agreement EX-4.1 Exhibit 4.1 ATEA PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT THIS FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of May 19, 2020, by and among Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Founder (as defined below), each of the investors listed on Schedule A hereto (together with any subsequent invest |
|
| October 9, 2020 |
S-1 Table of Contents As filed with the Securities and Exchange Commission on October 9, 2020 Registration No. |
|
| October 9, 2020 |
Consulting Agreement between the Registrant and Danforth Advisors, LLC EX-10.7 Exhibit 10.7 Amendment #1 to Consulting Agreement This Amendment No. 1 to the Consulting Agreement (“Amendment”) is made as of August 8, 2019 (“Effective Date”), by and between Atea Pharmaceuticals, Inc. (“Company”) and Danforth Advisors, LLC (“Consultant” or “Danforth”) and amends that certain Consulting Agreement by and between the Company and Danforth made effective as of July 31, 2019 |
|
| October 9, 2020 |
Lease Agreement between the Registrant and OPG 125 SUMMER OWNER (DE) LLC EX-10.6 Exhibit 10.6 125 SUMMER STREET BOSTON, MASSACHUSETTS OFFICE LEASE AGREEMENT BETWEEN OPG 125 SUMMER OWNER (DE) LLC, a Delaware limited liability company, AS LANDLORD AND ATEA PHARMACEUTICALS, INC., a Delaware corporation, AS TENANT OFFICE LEASE AGREEMENT This Office Lease Agreement (this “Lease”) is made and entered into as of November 18, 2016 (the “Effective Date”), by and between OPG 125 |
|
| October 9, 2020 |
Subsidiaries of the Registrant EX-21.1 Exhibit 21.1 SUBSIDIARIES OF ATEA PHARMACEUTICALS, INC. Legal Name of Subsidiary Jurisdiction of Organization Atea Pharmaceuticals Securities Corporation Massachusetts |
|
| October 9, 2020 |
Specimen Stock Certificate evidencing the shares of common stock EX-4.2 Exhibit 4.2 The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM — as tenants in common UNIF GIFT MIN ACT— Custodian TEN ENT — as tenants by the entireties (Cust) (Minor) JT TEN — as joint tenants with right of survivorship and not as tenants |
|
| October 9, 2020 |
Certificate of Incorporation of the Registrant, as amended (currently in effect) EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATEA PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Atea Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIF |
|
| August 7, 2020 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on August 7, 2020 as Amendment No. |
|
| August 7, 2020 |
DRSLTR Wesley C. Holmes Direct Dial: 617-948-6027 [email protected] 200 Clarendon Street Boston, Massachusetts 02116 Tel: +1.617.948.6000 Fax: +1.617.948.6001 www.lw.com FIRM / AFFILIATE OFFICES Beijing Moscow Boston Munich Brussels New York Century City Orange County Chicago Paris Dubai Riyadh August 7, 2020 Düsseldorf San Diego Frankfurt San Francisco Hamburg Seoul Hong Kong Shanghai Houston |
|
| June 19, 2020 |
EX-21.1 Exhibit 21.1 SUBSIDIARIES OF ATEA PHARMACEUTICALS, INC. Legal Name of Subsidiary Jurisdiction of Organization Atea Pharmaceuticals Securities Corporation Massachusetts |
|
| June 19, 2020 |
EX-3.2 Exhibit 3.2 AMENDMENT NO. 1 TO BYLAWS OF ATEA PHARMACEUTICALS, INC. (a Delaware corporation) Adopted as of June 29, 2018 This Amendment No. 1 (this “Amendment”) to the Bylaws of Atea Pharmaceuticals, Inc. (the “Corporation”) is made as of June 29, 2018 and adopted by the stockholders of the Corporation. Any term used herein that is not otherwise defined shall have the meaning ascribed to su |
|
| June 19, 2020 |
EX-3.1 Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ATEA PHARMACEUTICALS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Atea Pharmaceuticals, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIF |
|
| June 19, 2020 |
ATEA PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT EX-4.1 Exhibit 4.1 ATEA PHARMACEUTICALS, INC. FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT THIS FOURTH AMENDED AND RESTATED STOCKHOLDERS AGREEMENT (this “Agreement”), is made as of May 19, 2020, by and among Atea Pharmaceuticals, Inc., a Delaware corporation (the “Company”), the Founder (as defined below), each of the investors listed on Schedule A hereto (together with any subsequent invest |
|
| June 19, 2020 |
ATEA PHARMACEUTICALS, INC. 2013 EQUITY INCENTIVE PLAN EX-10.1 Exhibit 10.1 ATEA PHARMACEUTICALS, INC. 2013 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better a |
|
| June 19, 2020 |
DRS Table of Contents As confidentially submitted to the Securities and Exchange Commission on June 18, 2020 Registration No. |
